Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iopodic acid is a tri-iodinated benzene derivative classified as an oral cholecystographic agent and radiopaque contrast medium. It is used primarily to visualize the gallbladder and biliary tract during abdominal X-ray procedures due to its high lipid solubility and ability to block X-rays. Iopodic acid has also been used off-label for the treatment of hyperthyroidism (including Graves' disease), where it inhibits 5'-monodeiodinase type I and II enzymes, thereby reducing the peripheral conversion of thyroxine (T4) to triiodothyronine (T3). This results in decreased levels of active thyroid hormone. The drug is absorbed via passive diffusion in the small intestine after oral administration; bile salts enhance its absorption. Most of the drug is excreted via bile into feces with some renal elimination[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iopodic acid.